Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash & Current Investments (2017 - 2025)

Historic Cash & Current Investments for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $94.4 million.

  • Puma Biotechnology's Cash & Current Investments fell 241.61% to $94.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.4 million, marking a year-over-year decrease of 241.61%. This contributed to the annual value of $101.0 million for FY2024, which is 523.87% up from last year.
  • Puma Biotechnology's Cash & Current Investments amounted to $94.4 million in Q3 2025, which was down 241.61% from $96.0 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Cash & Current Investments peaked at $109.1 million during Q1 2021, and registered a low of $60.8 million during Q2 2022.
  • Over the past 5 years, Puma Biotechnology's median Cash & Current Investments value was $93.2 million (recorded in 2025), while the average stood at $89.1 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 4424.96% in 2022, then soared by 5047.39% in 2024.
  • Quarter analysis of 5 years shows Puma Biotechnology's Cash & Current Investments stood at $82.1 million in 2021, then decreased by 1.26% to $81.1 million in 2022, then increased by 18.34% to $95.9 million in 2023, then rose by 5.24% to $101.0 million in 2024, then decreased by 6.51% to $94.4 million in 2025.
  • Its last three reported values are $94.4 million in Q3 2025, $96.0 million for Q2 2025, and $93.2 million during Q1 2025.